Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 871 Published: August 30, 2022 Report Code: GDGMDHC22288IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    Powered by iSpeech

Fallopian Tube Cancer symptoms may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis.

The Fallopian Tube Cancer pipeline drugs market research report provides an analysis of the Fallopian Tube Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NA, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase) Diphtheria Toxin Like 2 or NAD, Tubulin, Vascular Endothelial Growth Factor Receptor 2, and Mast/Stem Cell Growth Factor Receptor Kit among others.

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Targets

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Targets

To know more about the targets in the Fallopian Tube Cancer pipeline drugs market , download a free report sample

Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action

The mechanisms of action of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria) Toxin Like 1 or NAD Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor among others.

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Mechanisms of Action

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Mechanisms of Action

To know more about the MoA in the Fallopian Tube Cancer pipeline drugs market , download a free report sample

Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Routes of Administration

The routes of administration in the Fallopian Tube Cancer pipeline drugs market are intravenous, oral, subcutaneous, intraperitoneal, intravenous drip, parenteral, intradermal, intratumor, intravesical, and intralesional among others.

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Routes of Administration

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Routes of Administration

To know more about the RoA in the Fallopian Tube Cancer pipeline drugs market , download a free report sample

Fallopian Tube Cancer Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Fallopian Tube Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, and Oligonucleotide among others.

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Molecule Types

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Molecule Types

To know more about the molecules in the Fallopian Tube Cancer pipeline drugs market , download a free report sample

Leading Companies in the Fallopian Tube Cancer Pipeline Drugs Market

Some of the leading companies in the Fallopian Tube Cancer pipeline drugs market are AstraZeneca Plc, GSK plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, Pharma Mar SA, Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, F. Hoffmann-La Roche Ltd, and Merck KGaA among others.

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Leading Companies

Fallopian Tube Cancer Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the Fallopian Tube Cancer pipeline drugs market , download a free report sample

Fallopian Tube Cancer Pipeline Drugs Market Report Overview

Key Targets Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NA, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase) Diphtheria Toxin Like 2 or NAD, Tubulin, Vascular Endothelial Growth Factor Receptor 2, and Mast/Stem Cell Growth Factor Receptor Kit
Key Mechanisms of Action Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria) Toxin Like 1 or NAD Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intraperitoneal, Intravenous Drip, Parenteral, Intradermal, Intratumor, Intravesical, and Intralesional
Key Molecule Types Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, and Oligonucleotide
Key Companies AstraZeneca Plc, GSK plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, Pharma Mar SA, Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, F. Hoffmann-La Roche Ltd, and Merck KGaA

Scope 

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

AB Science SA

AbbVie Inc

ADC Therapeutics SA

Advenchen Laboratories LLC

AiVita Biomedical Inc

Akeso Inc

Aldeyra Therapeutics Inc

Alkermes Plc

Alpine Immune Sciences Inc

Amgen Inc

Aminex Therapeutics Inc

Anixa Biosciences Inc

Apexigen Inc

APIM Therapeutics AS

Apollomics Inc

Aprea Therapeutics Inc

Aravive Inc

Arch Oncology Inc

Artios Pharma Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Basilea Pharmaceutica Ltd

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

Bio-Thera Solutions Ltd

BioAtla Inc

BioIntegrator

BioInvent International AB

BioNTech SE

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Celldex Therapeutics Inc

Celltrion Inc

Celsion Corp

Clovis Oncology Inc

Coherent Biopharma

Compugen Ltd

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

Cristal Therapeutics BV

CSPC Pharmaceutical Group Ltd

Daiichi Sankyo Co Ltd

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Co

Ellipses Pharma Ltd

ENB Therapeutics LLC

Exelixis Inc

F. Hoffmann-La Roche Ltd

FUJIFILM Toyama Chemical Co Ltd

Genelux Corp

Genentech USA Inc

Genmab AS

Gilead Sciences Inc

Gradalis Inc

Greenfire Bio LLC

GSK plc

Harpoon Therapeutics Inc

Hutchison MediPharma Ltd

I-Mab

Idience Co Ltd

ImmunityBio Inc

Immunocore Limited

ImmunoGen Inc

Immunotech Biopharm Ltd

IMPACT Therapeutics Inc

IMV Inc

Incyte Corp

Innovent Biologics Inc

Instil Bio Inc

InxMed (Beijing) Co Ltd

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Jina Pharmaceuticals Inc

Johnson & Johnson

Karyopharm Therapeutics Inc

Kidswell Bio Corp

Laekna Therapeutics Shanghai Co Ltd

Leap Therapeutics Inc

Lee’s Pharmaceutical Holdings Ltd

Lokon Pharma AB

MabVax Therapeutics Holdings Inc

Merck & Co Inc

Merck KGaA

Mereo Biopharma Group Plc

Mersana Therapeutics Inc

Mina Therapeutics Ltd

Mycenax Biotech Inc

Northlake International LLC

Novartis AG

NuCana Plc

Nurix Therapeutics Inc

Nuvation Bio Inc

OBI Pharma Inc

OncoC4 Inc

Oncoinvent AS

Onconic Therapeutics Co Ltd

OncoQuest Inc

Oncovir Inc

OncXerna Therapeutics Inc

Ono Pharmaceutical Co Ltd

Onxeo SA

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

Pharmicell Co Ltd

Pharos iBio Co Ltd

Pionyr Immunotherapeutics Inc

Plexxikon Inc

Precigen Inc

Prestige BioPharma Ltd

ProLynx LLC

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

R-Pharm US LLC

Recordati SpA

Regeneron Pharmaceuticals Inc

RemeGen Co Ltd

Rhizen Pharmaceuticals SA

Rigel Pharmaceuticals Inc

Samyang Biopharmaceuticals Corp

Sanofi

Scancell Holdings Plc

Seagen Inc

SELLAS Life Sciences Group Inc

Senhwa Biosciences Inc

Shanghai De Novo Pharmatech Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shattuck Labs Inc

Shenzhen Chipscreen Biosciences Co Ltd

Sorrento Therapeutics Inc

STADA Pharmaceuticals (Asia) Ltd

Sumitomo Pharma Co Ltd

Sutro Biopharma Inc

Synermore Biologics Co Ltd

SynOx Therapeutics Ltd

TILT Biotherapeutics Ltd

Tmunity Therapeutics Inc

Toray Industries Inc

Transgene SA

Ultimovacs AS

Vascular Biogenics Ltd

Verastem Inc

Viatris Inc

Vigeo Therapeutics Inc

Vivesto AB

Vyriad Inc

Xencor Inc

Xynomic Pharmaceuticals Holdings Inc

Zenith Epigenetics Ltd

Zentalis Pharmaceuticals Inc

Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fallopian Tube Cancer – Overview

Fallopian Tube Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fallopian Tube Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fallopian Tube Cancer – Companies Involved in Therapeutics Development

Fallopian Tube Cancer – Drug Profiles

Fallopian Tube Cancer – Dormant Projects

Fallopian Tube Cancer – Discontinued Products

Fallopian Tube Cancer – Product Development Milestones

Featured News & Press Releases

Jul 22, 2022: EMA recommends restricting use of cancer medicine Rubraca

Jul 05, 2022: EMA recommends granting a marketing authorisation for biosimilar Bevacizumab

May 31, 2022: Greenfire Bio to update progress on phase 1 clinical trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

May 19, 2022: EMA starts review of rucaparib

Feb 24, 2022: Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS

Dec 10, 2021: Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea

Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) first listing for Pamiparib

Feb 25, 2021: Viatris receives positive CHMP opinion for Abevmy for use as treatment of various cancers

Dec 28, 2020: Zai Lab announces inclusion of ZEJULA (Niraparib) in China’s National Reimbursement Drug List

Oct 05, 2020: Elevar Therapeutics and Taiba Middle East FZ partner to commercialize Apealea (paclitaxel micellar) in the Middle East and North Africa region

Jul 27, 2020: Elevar Therapeutics and Tanner Pharma Group announce global named patient program to provide access to Apealea (paclitaxel micellar)

Jun 22, 2020: Preclinical data for PRGN-3005 UltraCAR-T demonstrate superior expansion and persistence of UltraCAR-T compared to traditional CAR-T

Apr 30, 2020: GSK gets FDA approval for expanded use of ovarian cancer drug Zejula

Apr 20, 2020: Sutro Biopharma to host conference call, to provide clinical update on its STRO-002 Antibody-Drug Conjugate

Mar 16, 2020: Zai Lab announces acceptance of sNDA submission of ZEJULA (Niraparib) for first-line maintenance treatment of ovarian cancer in China by the NMPA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Fallopian Tube Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Fallopian Tube Cancer – Dormant Projects, 2022

Fallopian Tube Cancer – Discontinued Products, 2022

Fallopian Tube Cancer – Discontinued Products, 2022 (Contd..1)

List of Figures

List of Figures

Number of Products under Development for Fallopian Tube Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

Some of the targets of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NA, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase) Diphtheria Toxin Like 2 or NAD, Tubulin, Vascular Endothelial Growth Factor Receptor 2, and Mast/Stem Cell Growth Factor Receptor Kit among others.

The key mechanism of action of the Fallopian Tube Cancer pipeline drugs market are Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria) Toxin Like 1 or NAD Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor among others.

The routes of administration in the Fallopian Tube Cancer pipeline drugs market are intravenous, oral, subcutaneous, intraperitoneal, intravenous drip, parenteral, intradermal, intratumor, intravesical, and intralesional among others.

The molecule types in the Fallopian Tube Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, and Oligonucleotide among others.

Some of the leading companies in the Fallopian Tube Cancer pipeline drugs market are AstraZeneca Plc, GSK plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, Pharma Mar SA, Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, F. Hoffmann-La Roche Ltd, and Merck KGaA among others.

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.